Neogen Quarterly Income Statement
NASDAQ: NEOGHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Neogen revenue and earnings
In the quarter ended Aug 31, 2026, Neogen generated $222.8 million in revenue, up 6.5% from the same quarter a year earlier. Neogen reported a net loss of $11.9 million, compared with net income of $36.3 million a year earlier. Gross margin was 47.4% (up from 45.4%) and operating margin -0.8%.
Diluted earnings per share came in at -$0.05, down from $0.17.
Summary generated from market data by MetaCap's automated system. Methodology
Neogen income statement (quarterly)
| Quarter (USD) | Q1 20272026-08-31 | Q4 20262026-05-31 | Q3 20262026-02-28 | Q2 20262025-11-30 | Q1 20262025-08-31 | Q4 20252025-05-31 | Q3 20252025-02-28 | Q2 20252024-11-30 | Q1 20242024-08-31 | Q4 20242024-05-31 | Q3 20242024-02-29 | Q2 20242023-11-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 222.80M | 225.30M | 211.20M | 224.69M | 209.20M | 225.50M | 221.00M | 231.26M | 216.96M | 236.77M | 228.81M | 229.63M |
| Revenue growth (YoY) | +6.50% | -0.09% | -4.43% | -2.84% | -3.58% | -4.76% | -3.41% | +0.71% | -5.25% | -2.08% | +4.84% | -0.18% |
| Cost of Revenue | 117.30M | 117.50M | 112.20M | 118.01M | 114.20M | 132.60M | 110.70M | 117.93M | 112.04M | 123.29M | 111.93M | 112.86M |
| Gross Profit | 105.50M | 107.80M | 99.00M | 106.68M | 95.00M | 92.90M | 110.30M | 113.33M | 104.93M | 113.48M | 116.88M | 116.77M |
| Operating Expenses | 107.30M | 104.70M | 102.30M | 112.06M | 111.10M | 704.10M | 104.90M | 570.81M | 102.67M | 100.50M | 104.86M | 102.31M |
| Research & Development | 6.50M | 4.90M | 3.80M | 4.56M | 5.10M | 6.30M | 4.50M | 5.11M | 5.20M | 5.17M | 4.85M | 5.76M |
| Selling, General & Admin | 100.80M | 99.80M | 98.50M | 107.50M | 106.00M | 99.90M | 100.40M | 104.32M | 97.47M | 95.34M | 100.01M | 96.55M |
| Operating Income | -1.80M | 3.10M | -3.30M | -5.38M | -16.10M | -611.20M | 5.40M | -457.48M | 2.26M | 12.98M | 12.02M | 14.46M |
| Interest Expense | — | — | — | — | — | — | — | — | — | 10.79M | 10.50M | 10.27M |
| Other Income (Expense) | -13.10M | -15.20M | -17.00M | -14.99M | 59.90M | -20.00M | -15.10M | -19.09M | -17.87M | -19.37M | -17.84M | -18.21M |
| Pretax Income | -14.90M | -12.10M | -20.30M | -20.36M | 43.80M | -631.20M | -9.70M | -476.57M | -15.61M | -6.39M | -5.82M | -3.75M |
| Income Tax | -3.00M | -800.00K | -3.30M | -4.44M | 7.50M | -19.00M | 1.20M | -20.29M | -3.00M | -1.00M | -3.80M | -260.00K |
| Net Income | -11.90M | -11.30M | -17.00M | -15.92M | 36.30M | -612.20M | -10.90M | -456.28M | -12.61M | -5.39M | -2.02M | -3.49M |
| Net Income growth (YoY) | -132.78% | — | — | — | — | — | — | — | -938.92% | -196.81% | -124.69% | — |
| EPS (Basic) | -0.05 | -0.06 | -0.08 | -0.07 | 0.17 | -2.82 | -0.05 | -2.10 | -0.06 | -0.02 | -0.01 | -0.02 |
| EPS (Diluted) | -0.05 | -0.06 | -0.08 | -0.07 | 0.17 | -2.82 | -0.05 | -2.10 | -0.06 | -0.02 | -0.01 | -0.02 |
| Shares Outstanding (Basic) | 218.10M | — | 217.67M | 217.41M | 217.20M | — | 217.03M | 216.81M | 216.70M | — | 216.60M | 216.41M |
| Shares Outstanding (Diluted) | 218.10M | — | 217.67M | 217.41M | 217.30M | — | 217.03M | 216.81M | 216.70M | — | 216.60M | 216.41M |
| EBITDA | 27.30M | 32.50M | 25.62M | 23.50M | 13.00M | -580.90M | 34.75M | -427.44M | 32.06M | 41.82M | 41.67M | 43.93M |
| Gross Margin | 47.35% | 47.85% | 46.88% | 47.48% | 45.41% | 41.20% | 49.91% | 49.01% | 48.36% | 47.93% | 51.08% | 50.85% |
| Operating Margin | -81.00% | 138.00% | -1.56% | -2.39% | -7.70% | -271.04% | 2.44% | -197.82% | 104.00% | 5.48% | 5.25% | 6.30% |
| Net Margin | -5.34% | -5.02% | -8.05% | -7.09% | 17.35% | -271.49% | -4.93% | -197.30% | -5.81% | -2.28% | -88.00% | -1.52% |
This table shows 12 quarterly periods of Neogen's income statement, from Q1 2027 back to Q2 2024, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow NEOG's reporting calendar. What is a income statement?